# Cadrenal Therapeutics, Inc.: financial statements, quarterly

CVKD · Nasdaq · CIK 1937993 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cvkd.md) · [Financials](/companies/cvkd/financials.md) · [Filings](/companies/cvkd/filings.md) · [Insiders](/companies/cvkd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cvkd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of revenue | $k | [0.0 d](/filings/0001213900-23-084937.md) | [0.0 d](/filings/0001213900-24-021133.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [244](/filings/0001213900-24-095393.md) | [361 d](/filings/0001213900-25-023759.md) | [629](/filings/0001213900-25-040788.md) | [1,254](/filings/0001213900-25-073885.md) | [785](/filings/0001213900-25-107816.md) | [1,538 d](/filings/0001213900-26-036946.md) | [1,668](/filings/0001213900-26-053074.md) | [1,077](/filings/0001213900-26-089153.md) | [688](/filings/0001213900-25-107816.md) | [666 d](/filings/0001213900-26-036946.md) | [772](/filings/0001213900-26-053074.md) | [705](/filings/0001213900-26-089153.md) |
| Operating income | $k | [(1,143)](/filings/0001213900-24-095393.md) | [(1,264) d](/filings/0001213900-25-023759.md) | [(1,756)](/filings/0001213900-25-040788.md) | [(2,467)](/filings/0001213900-25-073885.md) | [(2,460)](/filings/0001213900-25-107816.md) | [(4,278) d](/filings/0001213900-26-036946.md) | [(3,928)](/filings/0001213900-26-053074.md) | [(3,734)](/filings/0001213900-26-089153.md) | [(2,734)](/filings/0001213900-25-107816.md) | [(3,065) d](/filings/0001213900-26-036946.md) | [(2,514)](/filings/0001213900-26-053074.md) | [(3,340)](/filings/0001213900-26-089153.md) |
| Interest expense | $k | [0.0 d](/filings/0001213900-23-084937.md) | [0.0 d](/filings/0001213900-25-023759.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,036)](/filings/0001213900-24-095393.md) | [(1,144) d](/filings/0001213900-25-023759.md) | [(1,663)](/filings/0001213900-25-040788.md) | [(2,393)](/filings/0001213900-25-073885.md) | [(2,408)](/filings/0001213900-25-107816.md) | [(4,187) d](/filings/0001213900-26-036946.md) | [(3,845)](/filings/0001213900-26-053074.md) | [(3,667)](/filings/0001213900-26-089153.md) | [(2,686)](/filings/0001213900-25-107816.md) | [(3,039) d](/filings/0001213900-26-036946.md) | [(2,497)](/filings/0001213900-26-053074.md) | [(3,323)](/filings/0001213900-26-089153.md) |
| Diluted EPS | $ per share | [(1.01)](/filings/0001213900-24-095393.md) | not reported | [(1.56)](/filings/0001213900-25-040788.md) | [(2.24)](/filings/0001213900-25-073885.md) | [(2.18)](/filings/0001213900-25-107816.md) | not reported | [(2.09)](/filings/0001213900-26-053074.md) | [(1.87)](/filings/0001213900-26-089153.md) | [(1.31)](/filings/0001213900-25-107816.md) | not reported | [(1.04)](/filings/0001213900-26-053074.md) | [(1.14)](/filings/0001213900-26-089153.md) |
| Basic EPS | $ per share | [(1.01)](/filings/0001213900-24-095393.md) | not reported | [(1.56)](/filings/0001213900-25-040788.md) | [(2.24)](/filings/0001213900-25-073885.md) | [(2.18)](/filings/0001213900-25-107816.md) | not reported | [(2.09)](/filings/0001213900-26-053074.md) | [(1.87)](/filings/0001213900-26-089153.md) | [(1.31)](/filings/0001213900-25-107816.md) | not reported | [(1.04)](/filings/0001213900-26-053074.md) | [(1.14)](/filings/0001213900-26-089153.md) |

- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | period not labelled (2025-08-06) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.4](/filings/0001213900-24-041014.md) | [6.6](/filings/0001213900-24-041014.md) | [5.0](/filings/0001213900-24-066107.md) | [4.4](/filings/0001213900-24-095393.md) | [10.0](/filings/0001213900-26-036946.md) | [7.3](/filings/0001213900-25-040788.md) | [5.6](/filings/0001213900-25-073885.md) | [5.0](/filings/0001213900-25-073885.md) | [3.9](/filings/0001213900-25-107816.md) | [4.0](/filings/0001213900-26-089153.md) | [2.3](/filings/0001213900-26-053074.md) | [2.4](/filings/0001213900-26-089153.md) |
| Current assets | $m | [8.5](/filings/0001213900-25-023759.md) | [7.0](/filings/0001213900-24-041014.md) | [5.4](/filings/0001213900-24-066107.md) | [4.7](/filings/0001213900-24-095393.md) | [10.1](/filings/0001213900-26-036946.md) | [7.9](/filings/0001213900-25-040788.md) | [6.0](/filings/0001213900-25-073885.md) | not reported | [4.1](/filings/0001213900-25-107816.md) | [4.3](/filings/0001213900-26-089153.md) | [2.9](/filings/0001213900-26-053074.md) | [5.6](/filings/0001213900-26-089153.md) |
| Total assets | $m | [8.5](/filings/0001213900-25-023759.md) | [7.0](/filings/0001213900-24-041014.md) | [5.5](/filings/0001213900-24-066107.md) | [4.7](/filings/0001213900-24-095393.md) | [10.1](/filings/0001213900-26-036946.md) | [8.0](/filings/0001213900-25-040788.md) | [6.0](/filings/0001213900-25-073885.md) | not reported | [4.1](/filings/0001213900-25-107816.md) | [4.3](/filings/0001213900-26-089153.md) | [2.9](/filings/0001213900-26-053074.md) | [5.6](/filings/0001213900-26-089153.md) |
| Current liabilities | $m | [0.8](/filings/0001213900-25-023759.md) | [0.9](/filings/0001213900-24-041014.md) | [1.5](/filings/0001213900-24-066107.md) | [1.3](/filings/0001213900-24-095393.md) | [2.7](/filings/0001213900-26-036946.md) | [1.8](/filings/0001213900-25-040788.md) | [1.7](/filings/0001213900-25-073885.md) | not reported | [1.4](/filings/0001213900-25-107816.md) | [1.6](/filings/0001213900-26-089153.md) | [1.1](/filings/0001213900-26-053074.md) | [1.5](/filings/0001213900-26-089153.md) |
| Total liabilities | $m | [0.8](/filings/0001213900-25-023759.md) | [0.9](/filings/0001213900-24-041014.md) | [1.5](/filings/0001213900-24-066107.md) | [1.3](/filings/0001213900-24-095393.md) | [2.7](/filings/0001213900-26-036946.md) | [1.8](/filings/0001213900-25-040788.md) | [1.7](/filings/0001213900-25-073885.md) | not reported | [1.4](/filings/0001213900-25-107816.md) | [1.6](/filings/0001213900-26-089153.md) | [1.1](/filings/0001213900-26-053074.md) | [1.5](/filings/0001213900-26-089153.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [7.7](/filings/0001213900-26-036946.md) | [6.2](/filings/0001213900-25-073885.md) | [4.0](/filings/0001213900-25-107816.md) | [3.4](/filings/0001213900-25-107816.md) | [7.4](/filings/0001213900-26-089153.md) | [6.1](/filings/0001213900-26-089153.md) | [4.3](/filings/0001213900-26-089153.md) | not reported | [2.7](/filings/0001213900-25-107816.md) | [2.7](/filings/0001213900-26-089153.md) | [1.8](/filings/0001213900-26-089153.md) | [4.1](/filings/0001213900-26-089153.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(628) d](/filings/0001213900-24-095393.md) | [(694) d](/filings/0001213900-25-023759.md) | [(1,836)](/filings/0001213900-25-040788.md) | [(1,529) d](/filings/0001213900-25-073885.md) | [(2,201) d](/filings/0001213900-25-107816.md) | [(1,791) d](/filings/0001213900-26-036946.md) | [(4,649)](/filings/0001213900-26-053074.md) | [(3,026) d](/filings/0001213900-26-089153.md) | [(2,357) d](/filings/0001213900-25-107816.md) | [(2,570) d](/filings/0001213900-26-036946.md) | [(3,002)](/filings/0001213900-26-053074.md) | [(2,233) d](/filings/0001213900-26-089153.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001213900-24-095393.md) | [0.0 d](/filings/0001213900-25-023759.md) | not reported | not reported | not reported | not reported | [3.3](/filings/0001213900-26-053074.md) | [0.0 d](/filings/0001213900-26-089153.md) | [1.9 d](/filings/0001213900-25-107816.md) | [0.0 d](/filings/0001213900-26-036946.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [8.0](/filings/0001213900-23-084937.md) | [10.8](/filings/0001213900-24-041014.md) | [11.7](/filings/0001213900-24-066107.md) | [1.0](/filings/0001213900-24-095393.md) | [1.1](/filings/0001213900-25-040788.md) | [1.1](/filings/0001213900-25-073885.md) | [1.1](/filings/0001213900-25-107816.md) | [1.8](/filings/0001213900-26-053074.md) | [2.0](/filings/0001213900-26-089153.md) | [2.0](/filings/0001213900-25-107816.md) | [2.4](/filings/0001213900-26-053074.md) | [2.9](/filings/0001213900-26-089153.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,567,592 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001213900-26-089153.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.